Global Azacitidine Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 77.51 Billion |
 Market Size (Forecast Year) |
USD 142.41 Billion |
 CAGR |
% |
| Major Markets Players |
>全球阿扎胞苷市场，按类型（99.5%、
阿扎胞苷市场分析和规模
阿扎胞苷是一类被称为去甲基化的药物。全球患有乳腺癌和黑色素瘤等慢性疾病的人数增加是推动阿扎胞苷市场增长的主要因素之一。一些医疗专业人士的推荐量增加得太快，而且没有起到应有的作用。主要市场参与者开发几种新药进一步影响了市场。
Data Bridge Market Research 分析，阿扎胞苷市场预计到 2030 年将达到 1.4241 亿美元，即 2022 年为 7751 万美元，预计在 2023 年至 2030 年的预测期内复合年增长率为 7.9%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
阿扎胞苷市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
类型（99.5%、<99.5%）、产品（Vidaza、通用 Vidaza）、用途（难治性贫血 (RA)、伴原始细胞过多的难治性贫血 (RAEB)、慢性粒单核细胞白血病 (CMMoL)、其他）、给药方式（注射、口服、其他）、分销渠道（医院药房、零售药房、网上药房）、最终用户（医院、家庭护理、专科诊所、其他） |
|
覆盖国家 |
北美洲的美国、加拿大和墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲其他地区 |
|
涵盖的市场参与者 |
Novartis AG (Switzerland), Sanofi (France), Pfizer Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Bausch Health Companies Inc. (Canada), AstraZeneca (U.K.), GSK plc (U.K.), H. Lundbeck A/S (Denmark), Takeda Pharmaceutical Company Limited (Japan), DAIICHI SANKYO COMPANY, LIMITED (Japan), Eisai Co., Ltd (Japan), Merz Pharma (Germany) |
|
Market Opportunities |
|
Market Definition
Azacitidine is the type of chemotherapy drug used to treat a group of blood or bone marrow disorders where the bone marrow fails to produce enough healthy blood cells. Several Individuals are suffering from MDS, and generally face complications such as anemia, infections, and easy bleeding or bruising. Azacitidine comes in the powder form to be mixed with water and injected subcutaneously or intravenously in a medical office or hospital outpatient department. It is generally injected once a day for 7 days.
Azacitidine Market Dynamics
Drivers
- Growing regulatory approval of drugs
Growing regulatory approval for the drugs that are used in the treatment of MDS treatment is projected to boost the market growth during the forecast period. For instance, Lupin received the U.S. FDA approval in November 2018 for its Decitabine for Injection, 50 mg/vial, single-dose vial, a generic version of Otsuka Pharmaceutical Co. Ltd.'s Dacogen for Injection, 50 mg/vial, single-dose vial. Lupin’s generic version is specified for treating patients with myelodysplastic syndromes (MDS). Furthermore, the U.S. FDA approved Inqovi tablets in July 2020 for treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This signifies an important advancement in treatment options for patients suffering from myelodysplastic syndrome (MDS) who previously used to receive intravenous therapy.
Opportunities
- Increasing Cancers of Cancer
Acute myeloid leukemia (AML) is often difficult to treat, particularly for older adults and those who don't respond well to standard chemotherapy treatment options. Multiple myeloma (MM) is also a type of cancer that is treated with azacitidine by slowing down the production of these abnormal white blood cells. This factor is boosting the market growth.
- Rising Awareness about the myelodysplastic syndrome (MDS) disease
Several government organizations and drug manufacturing companies are primarily focusing on spreading awareness about the myelodysplastic syndrome disease by providing funding for R&D of drugs which are used in the treatment of MDS and showing awareness programs about the disease. For instance, Grupo Biotoscana in October 2018, conducted a campaign to celebrate Myelodysplastic Syndrome World Awareness Day, on 25th October. GBT Grupo Biotoscana launched a campaign to raise awareness and educate about the disease.
Restraints/Challenges
- 组织延迟批准
很多公司除非药物专利终止，否则无法生产药物。因此，价值数十亿美元的药物失去专利的可能性很大。这阻碍了市场的增长。
本阿扎胞苷市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩张、市场技术创新。如需了解有关阿扎胞苷市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。
全球阿扎胞苷市场范围
阿扎胞苷市场根据类型、产品、应用、给药途径、分销渠道和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
类型
- 99.5％
- <99.5％
产品
- 维达莎
- 通用 Vidaza
应用
- 难治性贫血（RA）
- 难治性贫血伴原始细胞过多（RAEB）
- 慢性粒单核细胞白血病 (CMMoL)
- 其他的
给药途径
- 注射剂
- 口服
- 其他的
分销渠道
- 医院药房
- 零售药店
- 网上药店
终端用户
- 医院
- 家庭护理
- 专科诊所
- 其他的
阿扎胞苷市场区域分析/见解
对阿扎胞苷市场进行了分析，并按类型、产品、应用、给药途径、分销渠道和最终用户提供了市场规模洞察和趋势。
阿扎胞苷市场报告涉及的主要国家 包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。
由于医疗保健支出不断增加且医疗保健基础设施完善，北美在市场上占据主导地位。
由于对活性药物成分的消费需求增加，亚太地区被认为将迎来最有利可图的时期。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和全球阿扎胞苷市场份额分析
阿扎胞苷市场竞争格局提供了按竞争对手划分的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对阿扎胞苷市场的关注有关。
阿扎胞苷市场的主要参与者包括：
- 诺华公司（瑞士）
- 赛诺菲（法国）
- 辉瑞公司（美国）
- 强生私人有限公司（美国）
- 雅培（美国）
- Teva Pharmaceutical Industries Ltd.（以色列）
- Bausch Health Companies Inc.（加拿大）
- 阿斯利康（英国）
- 葛兰素史克公司 (英国)
- H. Lundbeck A/S（丹麦）
- 武田药品工业株式会社 (日本)
- 第一三共株式会社（日本）
- 卫材株式会社（日本）
- Merz Pharma（德国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
